Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis

Laboratory Investigation

Volumn 90, Issue 7, 2010, Pages 1102-1116

  Kristiansen, Glen ^a   MacHado, Eda ^b   Bretz, Niko ^c   Rupp, Christian ^c   Winzer, Klaus Jürgen ^d   König, Anne Kathleen ^c   Moldenhauer, Gerhard ^c   Marmé, Frederik ^e   Costa, Julia ^b   Altevogt, Peter ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CD24; glycans; monoclonal antibody; selectins; Siglecs

Indexed keywords

CD24 ANTIGEN; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD24; MONOCLONAL ANTIBODY ML 5; MONOCLONAL ANTIBODY SWA11; PADGEM PROTEIN; SELECTIN; SIGLEC 5 PROTEIN; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DIFFERENTIATION ANTIGEN; LECTIN; LEUKOCYTE ANTIGEN; SIGLEC5 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CONTROLLED STUDY; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TISSUE MICROARRAY; WESTERN BLOTTING; BREAST TUMOR; CARCINOMA; COMPARATIVE STUDY; FEMALE; IMMUNOLOGY; KIDNEY TUMOR; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD; ANTIGENS, CD24; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; FEMALE; HUMANS; KIDNEY NEOPLASMS; LECTINS; MALE; P-SELECTIN; PROSTATIC NEOPLASMS;

EID: 77954166926     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.70     Document Type: Article

References (52)

1. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004;35:255-262.
2. Kay R, Rosten PM, Humphries RK. CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol 1991;147:1412-1416.
3. Wenger RH, Ayane M, Bose R, et al. The genes for a mouse hematopoietic differentiation marker called the heat-stable antigen. Eur J Immunol 1991;21:1039-1046.
4. Wang L, Lin S, Rammohan KW, et al. A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet 2007;3:e49.
5. Zhou Q, Rammohan K, Lin S, et al. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci USA 2003;100:15041-15046.
6. Burchell JM, Mungul A, Taylor-Papadimitriou J. O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia 2001;6:355-364.
7. Kannagi R. Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression\the Warburg effect revisited. Glycoconj J 2004;20:353-364.
8. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 2006;7:599-604.
9. Pinho S, Marcos NT, Ferreira B, et al. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett 2007;249:157-170.
10. Bleckmann C, Geyer H, Lieberoth A, et al. O-glycosylation pattern of CD24 from mouse brain. Biol Chem 2009;390:627-645.
11. Bleckmann C, Geyer H, Reinhold V, et al. Glycomic analysis of N-linked carbohydrate epitopes from CD24 of mouse brain. J Proteome Res 2009;8:567-582.
12. Aigner S, Ramos CL, Hafezi MA, et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. Faseb J 1998;12:1241-1251.
13. Friederichs J, Zeller Y, Hafezi-Moghadam A, et al. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000;60:6714-6722.
14. Fukukawa T, Matsuzaki H, Haruta Y, et al. New monoclonal antibodies SN3, SN3a, and SN3b directed to sialic acid of glycoprotein on human non-T leukemia cells. Exp Hematol 1986;14:850-855.
15. Weber E, Lehmann HP, Beck-Sickinger AG, et al. Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-proline. Clin Exp Immunol 1993;93:279-285.
16. Salamone MC, Rosselot C, Salamone GV, et al. Antibodies recognizing CD24 LAP epitope on human T cells enhance CD28 and IL-2 T cell proliferation. J Leukoc Biol 2001;69:215-223.
17. Runz S, Keller S, Rupp C, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol 2007;107:563-571.
18. Runz S, Mierke CT, Joumaa S, et al. CD24 induces localization of beta1 integrin to lipid raft domains. Biochem Biophys Res Commun 2008;365:35-41.
19. Sousa VL, Brito C, Costa J. Deletion of the cytoplasmic domain of human alpha3/4 fucosyltransferase III causes the shift of the enzyme to early Golgi compartments. Biochim Biophys Acta 2004;1675:95-104.
20. Grabenhorst E, Nimtz M, Costa J, et al. In vivo specificity of human alpha1,3/4-fucosyltransferases III-VII in the biosynthesis of LewisX and Sialyl LewisX motifs on complex-type N-glycans. Coexpression studies
21. from bhk-21 cells together with human beta-trace protein. J Biol Chem 1998;273:30985-30994.
22. Jackson D, Waibel R, Weber E, et al. CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res 1992;52:5264-5270.
23. Aigner S, Sthoeger ZM, Fogel M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89:3385-3395. (Pubitemid 27229826)
24. Crystal AS, Morais VA, Pierson TC, et al. Membrane topology of gamma-secretase component PEN-2. J Biol Chem 2003;278: 20117-20123.
25. Sammar M, Aigner S, Hubbe M, et al. Heat-stable antigen (CD24) as ligand for mouse P-selectin. Int Immunol 1994;6:1027-1036.
26. Aigner S, Ruppert M, Hubbe M, et al. Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol 1995;7:1557-1565.
27. Schabath H, Runz S, Joumaa S, et al. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 2006;119: 314-325.
28. Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003;9:4906-4913.
29. Weber A, Kristiansen I, Johannsen M, et al. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer 2008;8:369.
30. Chen GY, Tang J, Zheng P, et al. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009;323:1722-1725.
31. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007;7:255-266.
32. Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 2007;87:851-857.
33. Escrevente C, Machado E, Brito C, et al. Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines. Int J Oncol 2006;29:557-566.
34. Kristiansen G, Pilarsky C, Pervan J, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004;58:183-192.
35. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988. (Pubitemid 36418143)
36. Kristiansen G, Pilarsky C, Wissmann C, et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005;205:359-376.
37. Senner V, Sturm A, Baur I, et al. CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol 1999;58:795-802.
38. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001;98:1176-1181.
39. Kristiansen G, Denkert C, Schluns K, et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002;161:1215-1221.
40. Kristiansen G, Schluns K, Yongwei Y, et al. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 2003;88:231-236.
41. Weichert W, Denkert C, Burkhardt M, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005;11:6574-6581.
42. Sano A, Kato H, Sakurai S, et al. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol 2009;16:506-514.
43. Chou YY, Jeng YM, Lee TT, et al. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 2007;14:2748-2758.
44. Sagiv E, Memeo L, Karin A, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006;131:630-639.
45. Smith SC, Oxford G, Wu Z, et al. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006;66:1917-1922.
46. Lee HJ, Kim DI, Kwak C, et al. Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance. Urology 2008;72:603-607.
47. Su MC, Hsu C, Kao HL, et al. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett 2006;235:34-39.
48. Kim KH, Choi JS, Kim JM, et al. Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium. Histol Histopathol 2009;24:309-316.
49. Mylona E, Giannopoulou I, Fasomytakis E, et al. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 2008;39:1096-1102.
50. Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005;11:1154-1159.
51. Surowiak P, Materna V, Paluchowski P, et al. CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases. Anticancer Res 2006;26:629-634.
52. Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry 2008;47:6991-7000.